Massachusetts’ top health official predicts that coverage for GLP-1 weight-loss medications will return in just a few years. Commercial insurers and state agencies had dropped these benefits due to high costs, but an anticipated “price crash” could lead to renewed coverage.
The Food and Drug Administration has warned over 100 companies, including Hims, about advertising claims tied to compounded weight-loss drugs. Regulators have labeled some marketing strategies as “false or misleading,” marking a significant push for stricter oversight.
Renee Graziano, best known for her role on “Mob Wives,” has a firm message for those criticizing Serena Williams and other celebrities who have used weight-loss drugs: back off. At a movie premiere, Graziano urged doubters to consult their doctors if they feel jealous or concerned about others’ weight-loss choices.
Viking Therapeutics’ experimental pill helped patients lose 12.2 % of their body weight in just 13 weeks—better than Eli Lilly’s latest effort but still shy of Novo Nordisk’s own results. Yet it was Novo Nordisk’s shares that “popped,” underscoring how the race for obesity drugs can move markets in unexpected ways.
